Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.75.

ZURA has been the topic of a number of recent analyst reports. Leerink Partners upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. Finally, Wall Street Zen lowered shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ZURA. Bank of America Corp DE raised its holdings in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares during the period. Scientech Research LLC bought a new position in shares of Zura Bio in the third quarter valued at about $45,000. Savant Capital LLC lifted its stake in shares of Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after buying an additional 21,249 shares during the last quarter. Forefront Wealth Partners LLC acquired a new stake in shares of Zura Bio during the 3rd quarter worth about $93,000. Finally, Armistice Capital LLC lifted its stake in shares of Zura Bio by 1.6% during the 3rd quarter. Armistice Capital LLC now owns 1,560,000 shares of the company’s stock worth $6,755,000 after buying an additional 24,000 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

Zura Bio Price Performance

NASDAQ ZURA opened at $5.77 on Thursday. The company’s fifty day moving average is $4.77 and its two-hundred day moving average is $3.44. Zura Bio has a 52-week low of $0.97 and a 52-week high of $6.63. The firm has a market capitalization of $375.17 million, a price-to-earnings ratio of -8.88 and a beta of 0.21.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). As a group, sell-side analysts expect that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.